Review
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Pharmacol. Dec 9, 2014; 3(4): 120-139
Published online Dec 9, 2014. doi: 10.5497/wjp.v3.i4.120
Phosphoprotein phosphatase 1-interacting proteins as therapeutic targets in prostate cancer
Juliana Felgueiras, Margarida Fardilha
Juliana Felgueiras, Margarida Fardilha, Laboratory of Signal Transduction, Centre for Cell Biology, Biology Department and Health Sciences Department, University of Aveiro, Campus de Santiago, 3810-193 Aveiro, Portugal
Author contributions: Felgueiras J and Fardilha M contributed to this paper.
Supported by Fundação para a Ciência e Tecnologia (FCT) (PTDC/QUI-BIQ/118492/2010) and Fundo Europeu de Desenvolvimento Regional (FEDER) (FCOMP-01-0124-FEDER-020895), Portugal
Correspondence to: Margarida Fardilha, PhD, Laboratory of Signal Transduction, Centre for Cell Biology, Biology Department and Health Sciences Department, University of Aveiro, Campus de Santiago, 3810-193 Aveiro, Portugal. mfardilha@ua.pt
Telephone: +351-918-143947 Fax: +351-234-377220
Received: June 29, 2014
Revised: September 1, 2014
Accepted: September 23, 2014
Published online: December 9, 2014
Core Tip

Core tip: Protein kinases and phosphatases are challenging and valuable therapeutic targets for cancer. Here, we revise the relevance of phosphoprotein phosphatase 1 and its interactors for prostate carcinogenesis. Although only 4 complexes are characterized in human prostate cancer models, 81 additional interactors are expressed in human prostate tissue and, at least, 29 of which are involved in prostate carcinogenesis. This complex network has promising roles in the development of new therapies for prostate cancer. Therefore, efforts should be made in order to characterize their biological significance in prostate carcinogenesis.